MedTrace Logo

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

NCT00028314 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2013-07-29

No results posted yet for this study

Summary

The goals of this study are to find out if fat wasting and weight loss in the arms and legs of HIV patients taking highly active antiretroviral therapy (HAART) are caused by nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and if wasting can be reversed if the NRTI is stopped and replaced with other anti-HIV drugs.

Conditions

  • HIV Infections
  • Lipodystrophy
  • Wasting Disease

Interventions

DRUG

Abacavir sulfate

DRUG

Atazanavir/Ritonavir

DRUG

Lopinavir/Ritonavir

DRUG

Nevirapine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Robert L Murphy, MD · Northwestern University Medical Center

  • Pablo Tebas, MD · University of Pennsylvania, Adult Clinical Trials Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00028314 on ClinicalTrials.gov